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1074Objectives: The analysis of exhaled breath is a promising noninvasive tool for the diagnosis of lung cancer, but
its clinical relevance has yet to be established.We report the analysis of exhaled volatile carbonyl compounds for
the identification of specific carbonyl cancer markers to differentiate benign pulmonary disease from early-stage
lung cancer and to compare its diagnostic accuracy with positron emission tomography (PET) scans.
Methods: Aminooxy-coated silicon microchips were used for the selective capture of exhaled carbonyls by an
oximation reaction. Breath samples were collected then directed through the silicon chips by applying a vacuum.
Carbonyl adducts were analyzed by Fourier transform mass spectrometry. Eighty-eight control subjects, 107
patients with lung cancer (64 stage 0, I, or II), 40 patients with benign pulmonary disease, and 7 patients
with a solitary pulmonary metastasis participated. Analysis of cancer markers was performed blinded to the
pathologic results.
Results: Four carbonyls were defined as cancer markers with significantly higher concentrations in patients with
lung cancer. The number of increased cancer markers distinguished benign disease from both early and stage III
and IV lung cancer. For early-stage disease, defining greater than 2 increased markers as diagnostic of lung can-
cer resulted in 83% sensitivity and 74% specificity. PET scans for this same cohort resulted in 90% sensitivity
but only 39% specificity. Markers normalized for 3 of the 4 markers after resection of the lung cancer.
Conclusions:Analysis of specific exhaled carbonyls can differentiate early lung cancer from benign pulmonary
disease. Breath analysis was more specific than PET for a lung cancer diagnosis. Judicious use of these data may
expedite the care of patients with lung cancer. (J Thorac Cardiovasc Surg 2014;148:1074-81)With the advent and increasing acceptance of computed to-
mography (CT) screening for lung cancer, the importance
of distinguishing benign from malignant intrathoracic dis-
ease is increasing. The reported 20% reduction in lung can-
cer mortality from the National Lung Cancer Screening
Trial is partially offset by the morbidity, cost and occasional
mortality incurred by pursuing nonmalignant pulmonary
nodules and adenopathy.1
Given a resectable pulmonary nodule, and depending on
its degree of suspicion, there are multiple options for diag-
nostic workup.2 Serial CT scanning to observe growth, res-
olution, or stability is commonly used for subcentimeter
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The Journal of Thoracic and Cardiovascular Surof the lesion may be used to assess the probability of malig-
nancy in nodules larger than 8 mm. Bronchoscopy and
percutaneous biopsy are options for tissue acquisition but
the associated costs and risks are significant. In addition,
diagnostic yields are highly conditional with respect to tu-
mor size, location, and operator skill. Proceeding directly
to surgical resection is appropriate when the probability
of malignancy is high and the surgical risk is low.
Conversely, surgical resection of nonmalignant disease is
a clinical failure because, in most such instances, the natural
course of the benign process would never have harmed the
patient. Furthermore, PET scans are frequently falsely pos-
itive both in cases of solitary pulmonary nodules and in
cases with hilar and mediastinal adenopathy. All may lead
to increased clinical suspicion of lung cancer and an obliga-
tion to rule out malignancy by surgical intervention. Thus, it
is important to develop reliable methods that minimize the
diagnostic burden to patients who have no significant dis-
ease while expediting treatment in patients who have lung
cancer.2-4
Breath analysis of patients with suspected lung cancer is
a developing modality with the potential to fulfill this goal.5
Linus Pauling first studied the volatile constituents of breath
in individuals maintained on an elemental diet in 1971.6 In
recent years, the analysis of exhaled breath has become a
broad research frontier.5,7,8 Several approaches have been
developed, including sensor arrays,9-13 proton transfergery c September 2014
Abbreviations and Acronyms
ATM ¼ 2-(aminooxy)-N,N,N-
trimethylethanammonium
CT ¼ computed tomography
ECM ¼ elevated cancer marker
FT ¼ Fourier transform
GC ¼ gas chromatography
ICR ¼ ion cyclotron resonance
MS ¼ mass spectrometry
PET ¼ positron emission tomography
SUV ¼ standardized uptake value
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Sreaction mass spectrometry,14,15 selected ion flow tube
mass spectrometry,16,17 and gas chromatography–mass
spectrometry.18-23
Reports of breath analysis of patients who have lung can-
cer have indicated a host of associated compounds and pro-
files5,19,24; however, the diagnostic usefulness of breath
analysis has not been established by these results. The
composition of breath ranges from molecular hydrogen to
more than 1000 volatile organic compounds and
nonvolatile condensates.5,7,25,26 When analyzing such a
broad data set, the potential for false leads and
confounding factors increases. The method described here
focuses selectively on aldehydes and ketones, volatile
carbonyl compounds in breath. This approach was chosen
because increased levels of carbonyls have been reported
in exhaled breath of patients with lung cancer.18-22
Recently, we reported the identification of 4 carbonyl
markers that distinguish lung cancer from benign disease,
lung cancer histology, and non–small lung cancer
stages.27 This report focuses on the clinical usefulness of
this diagnostic method in differentiating early-stage lung
cancer from benign pulmonary disease. The diagnostic
accuracy of breath analysis is compared with the PET stan-
dardized uptake value (SUV). To the best of our knowledge,
this is the first comparison of a breath analysis diagnostic
method with PET SUV results. We also report that a variety
of cancers metastatic to the lung produce increased levels of
the same carbonyl markers. We also show that the increased
carbonyl markers return to the level of healthy controls after
resection of malignancy.MATERIALS AND METHODS
The Silicone Microreactor Chips
The microreactor chips were fabricated from 10-cm silicon chips
using previously published microelectromechanical systems fabrication
techniques.28,29 The size of the silicon chip is similar to the size of a
dime and consists of an array of thousands of micropillars in the
microfluidic channel to uniformly distribute gas flowing through the
channel. A quaternary ammonium compound, 2-(aminooxy)-N,N,N-
trimethylethanammonium (ATM) iodide was used to coat the surfaces of
the micropillars as previously described.28,29 ATM adsorbs to the siliconThe Journal of Thoracic and Cardioxide surfaces of the micropillars via electrostatic and hydrogen bond
interactions. ATM chemoselectively traps carbonyl compounds in
exhaled breath by means of oximation reactions. Capture efficiencies of
98% or more have been verified for carbonyl compounds.29
Fourier Transform–Ion Cyclotron Resonance–Mass
Spectrometry
A hybrid linear ion trap Fourier transform (FT)–ion cyclotron resonance
(ICR)–mass spectrometer (MS) (Finnigan LTQ FT, Thermo Electron,
Bremen, Germany) equipped with a TriVersaNanoMate ion source
(AdvionBioSciences, Ithaca, NY) with an electrospray chip (nozzle inner
diameter 5.5 mm) was used to analyze all breath samples. The TriVersaNa-
noMatewas operated in positive ion mode by applying 2.0 kVwith no head
pressure. ATM and its adducts are cations that do not need further
ionization. These uniformly charged molecules are an important advantage
of using ATM for capture of carbonyl compounds and for analysis by
FT-ICR-MS.29 The detailed procedure for analysis by FT-ICR-MS has
been previously delineated.29
Collection of Breath Samples
The detailed research protocol for the collection of exhaled breath sam-
ples was approved by the Institutional Review Board at the University of
Louisville. All study participants signed informed consent before providing
breath samples. One liter of breath was collected into a Tedlar bag (Sigma-
Aldrich, St Louis, Mo) from a single exhalation from each participant.
Breath samples were first collected from 88 healthy controls; 45 were
current smokers and 43 were never smokers. A total of 171 patients with
suspected or confirmed cancer of the lung participated. Primary lung cancer
was present in 107 patients (97 non–small cell lung cancer, 8 small cell
lung cancer, 1 combined small and non–small cell lung cancer, and 1
carcinoid tumor), and 40 patients had benign pulmonary disease (single
or multiple pulmonary nodules and/or mediastinal adenopathy). Age and
smoking information for the 3 groups is summarized in Table 1. Healthy
controls and patients with benign pulmonary disease were younger than
the patients with lung cancer. Smoking history was similar. Seven
additional patients had a solitary metastasis to the lung. Five patients
with presumptive lung cancer were treated with radiation therapy without
tissue confirmation and were excluded from the analysis. Twelve patients
were excluded because a diagnosis had not yet been reached.
The procedure for the capture of carbonyl compounds in air and exhaled
breath has been described previously.28,29 In brief, the exhaled breath
collected in 1-L Tedlar bags was drawn through the microreactor chip by
applying a vacuum. After this process, ATM adducts in the microreactor
chip were eluted with 100 mL of methanol from a slightly pressurized small
vial. Ninety-nine percent of ATM adducts were recovered. The eluted
solution was analyzed directly by FT-ICR-MS. A known amount of
deuterated acetone completely reacted with ATM (ATM-acetone-d6) in
methanol was added to the eluted solution as an internal reference. The con-
centrations of all carbonyl compounds in exhaled breathwere determined by
comparison of the relative abundance with that of added ATM–acetone-d6.Data Analysis
As previously described, analysis of carbonyl concentrations in breath
samples of patients was performed with 88 healthy controls followed by
the first 10 confirmed cases of lung cancer. Four carbonyl cancer markers
were identified as being higher than healthy control levels and served as pre-
sumptive cancermarkers in all subsequent analyses betweenhealthy controls
and patient subsets.27Carbonyl concentrations for all exhaled breath samples
were analyzed by theWilcoxon test to determine statistically significant dif-
ferences between groups. Because the concentrations of the carbonyl com-
pounds detected had a nonnormal distribution, the Wilcoxon test was used
instead of analysis of variance. The Wilcoxon tests were performed using
Minitab version 16.0 (Mimitab, Inc, State College, Pa).diovascular Surgery c Volume 148, Number 3 1075
TABLE 1. Description of the patients
Subjects Total no.
Average age,
y ± standard
deviation
Smoking history
Current Former Never
Healthy controls 88 42.2  14.2 45 0 43
Benign pulmonary
disease
40 50.9  14.5 12 14 14
Lung cancer 107 65.8  10.1 44 51 12
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Four carbonyl compounds, 2-butanone (C4H8O2)
(P<.0001), 3-hydroxy-2-butanone (C4H8O2) (P<.0001),
2-hydroxyacetaldehyde (C2H4O2) (P < .0001), and
4-hydroxyhexenal (C6H10O2) (P ¼ .0045) were identified
as significantly increased in patients with lung cancer
compared with the healthy control group.27 The carbonyl
marker concentrations in the healthy control, benign pulmo-
nary disease, and lung cancer groups are presented in
Figure 1. Although the median cancer marker concentra-
tions of patients with lung cancer are significantly higher
than that of both healthy controls and patients with benign
disease, there is overlap between the concentration ranges
of the cancer markers between the groups. Thus, no single
cancer marker was sufficient to differentiate malignant
from benign disease. This finding prompted us to define
an elevated cancer marker (ECM) concentration as one
that exceeds the range of the healthy control distribution.
Therefore, a given patient may have 0 to 4 ECMs.
Table 2 presents a matrix relating the number of ECMs to
lung cancer stage and patients with benign pulmonaryFIGURE 1. The box plots of the 4 cancer markers for the healthy control, benig
B, 3-hydroxy-2-butanone; C, 2-acetacetaldehyde; D, 4-hydroxyhexenal. P valu
sents the median, lower, and upper quartiles (25th to 75th percentiles). HC, He
patient group; ESLC, early-stage lung cancer; 4-HHE, 4-hydroxyhexenal.
1076 The Journal of Thoracic and Cardiovascular Surdisease. The matrix coefficients represent the number of pa-
tients in each disease set with a given number of ECMs.
Ninety-four of 107 patients with lung cancer have 2 or
more ECMs. Thirty-one of 40 patients with benign pulmo-
nary disease have less than 2 ECMs. Only 1 patient with
stage III cancer demonstrated less than 2 ECMs. A logistic
regression model consisting of actual concentrations of
volatile compounds showed that C2H4O2 (odds ratio,
44.4; P< .05) was an independent predictor of cancer. A
receiver operating curve based on the logistic regression
model showed 86% area under the curve.
Sixty-four patients were identified with early-stage lung
cancer (stage 0, I, or II) (Table 2). Fifty-two (81.3%) of
these patients had 2 or more ECMs. Eleven patients with
lung cancer had less than 2 ECMs. Ten were stage IA or
0. Nine had an adenocarcinoma and 1 had squamous cell
carcinoma. The remaining false-negative patient had a
lymphocyte-rich sarcomatoid cancer and was stage IIB.
The sensitivity and specificity of breath analysis varies
according to the number of ECMs that define a positive
result. Comparing patients with early-stage lung cancer
with those with benign disease, if 3 or more ECMs are
chosen as a predictor of cancer, then a sensitivity of 55%
and a specificity of 95% is achieved. If 2 or more ECMs
are chosen, the sensitivity increases to 81% and the
specificity decreases to 74%. Likewise, if 1 or more ECM
is chosen, the sensitivity is 95% and the specificity is
45%. When applying breath analysis to tumors of 2.5 cm
or smaller, the sensitivity and specificity for 2 or
more ECMs were 74% (28 of 38) and 81% (17 of 21),
respectively, and for 3 or more ECMs, the sensitivityn pulmonary disease patient and lung cancer patient groups. A, 2-Butanone;
es apply to the benign versus lung cancer patient groups. The box plot pre-
althy control group; BN, benign pulmonary patient group; LC, lung cancer
gery c September 2014
TABLE 2. Sensitivity and specificity based on the number of elevated
cancer markers in lung cancer and benign pulmonary disease
Patients
Elevated cancer markers
4 3 2 1 0
Early stage, stage 0, I, II (n) 14 21 17 7 5
Sensitivity (%) 21 55 81 92
Specificity (%) 100 95 74 45
All-stage cancer (n) 30 42 22 8 5
Sensitivity (%) 28 67 88 95
Specificity (%) 100 95 77 45
Benign pulmonary nodule 0 2 7 13 18
Sensitivity and specificity based on cumulatively positive elevated cancer markers;
eg, sensitivity under the column headed 3 means sensitivity for 3 or more ECMs.
Bousamra et al Evolving Technology/Basic Scienceand specificity were 50% (19 of 38) and 95% (20 of
21), respectively (Figure 2). For tumors greater than
2.5 cm, breath analysis was always positive with 2 or
more ECMs.
Among patients with benign pulmonary nodules, 27%
had multiple nodules and adenopathy, 27% had a solitary
nodule, 22% had multiple nodules, 17% had a solitary
nodule and adenopathy, and 5% had adenopathy. The
mean size of the largest pulmonary nodule for a given pa-
tient was 2.1  1.2 cm. A tissue diagnosis was obtained
in 29 (73%) patients by bronchoscopy, CT-guided biopsy,
or surgical biopsy. Of these patients, 15 (50%) had a gran-
ulomatous process, 11 (36.7%) had inflammatory cells, and
3 (10.0%) had pneumonia. Those patients who did not un-
dergo a biopsy had low clinical suspicion for cancer and
were followed with serial CT scans.
A PET scan was performed in 93 (87%) of the patients
with lung cancer and 31 (78%) of the patients with benignFIGURE 2. Elevated carbonyl markers (ECMs) and positron emission tomog
(n ¼ 6) are identified by red circles. All tumors>2.5 cm have 2 ECMs, 35 tu
The Journal of Thoracic and Carpulmonary disease. For the entire cohort, the sensitivity and
specificity using PET scans were 92.5% and 38.7%,
respectively, compared with 88% (P ¼ .4) and 77.0%
(P ¼ .004), respectively, for breath analysis when ECMs
were set at 2 or more. Comparing early-stage lung cancer
(n ¼ 64) and benign pulmonary disease, the diagnostic
sensitivity and specificity of PET scans were 90.3% and
38.7%, respectively. The sensitivity and specificity of
breath analysis for these patients were 81% (P ¼ .3) and
74.0% (P¼ .002), respectively. Thus, PET scans and breath
analysis had similar sensitivity; however, the specificity of
breath analysis was nearly double that of PET scan.
Focusing on 37 patients with stage 0 and I tumors that
were less than 3.0 cm yields similar results. Breath analysis
was correctly diagnostic of lung cancer in this group for 27
patients, resulting in a sensitivity of 73.0%. PET scan accu-
rately diagnosed lung cancer in 30 patients, resulting in a
similar sensitivity of 81%.
Seven patients had isolated metastases to the lung. They
also demonstrated ECMs in proportions similar to patients
with lung cancer. Primary sites included the colon (n ¼ 3;
3, 2, 1 ECMs), skin melanoma (n¼ 2; 3, 1 ECMs), prostate
(n ¼ 1; 4 ECMs), and breast (n ¼ 1; 3 ECMs).
Breath was also collected from 20 patients with
early-stage lung cancer at least 1 month after complete
resection. Figure 3 shows box plots of the 4 cancer
markers identified. The concentrations of 2-butanone,
2-hydroxyacetaldehyde, and 4-hydroxyhexenal are signifi-
cantly reduced after resection, however the reduction in
3-hydroxy-2-butanone concentration did not achieve
statistical significance.raphy (PET) results in early-stage lung cancer. False-negative PET scans
mors are>2 cm and 19 are 2 cm.
diovascular Surgery c Volume 148, Number 3 1077
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FIGURE 3. Comparison of box plots of the 4 carbonyl markers before and after early-stage cancer resection. The box plot presents the median, lower,
and upper quartiles (25th to 75th percentiles). A, 2-Butanone, P ¼ .0001; B, 3-hydroxy-2-butanone, P ¼ .164; C, 2-acetaldehyde, P ¼ .0004;
D, 4-hydroxyhexenal, P ¼ .0005. 4-HHE, 4-hydroxyhexenal.
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Exhaled breath analysis of patients with lung cancer
identified 4 increased carbonyl compounds that served as
cancer markers. Among patients with lung cancer, 3 or 4
ECMs produced a specificity of 95%. Furthermore, 60%
of patients with early-stage lung cancer had 3 or more
ECMs. A positive breath result with 3 or 4 ECMs could
direct care to surgical resection as the next step for patients
with low suspicion of metastasis. Conversely, breath anal-
ysis rarely yields a false-negative result in advanced stages
of lung cancer and has a much lower false-positive rate for
benign disease compared with PET scans. Thus, if the pre-
test probability of benign disease is high, performing a
breath analysis as the next study rather than a PET scan
may save patients from invasive biopsy procedures.
Pulmonary nodules associated with a negative breath
analysis result may still require biopsy or repeated imaging
depending on their degree of suspicion because 24% of pa-
tients with stage 0 and stage I lung cancer had fewer than 2
ECMs. One patient with stage III and 1 with stage II lung
cancer had 1 ECM and no ECMs, respectively. As a corol-
lary, it seems unlikely that this breath analysis method could
supplant CT as a primary screening tool because of the sig-
nificant false-negative rate. Its primary potential is in
conjunction with a positive result on a CT scan. It remains
to be determined what proportion of subcentimeter malig-
nant pulmonary nodules will be diagnosed by combined
CT screening and breath analysis.1078 The Journal of Thoracic and Cardiovascular SurThere are numerous reports of breath analysis methods
for lung cancer detection.6,9-22,30-32 Most have involved
complicated concentration techniques and data analysis,
making clinical application remote. The current method is
simple for the patient and processing and analysis are
straightforward. FT-ICRS-MS analysis is direct with un-
equivocal identification of molecular formulae by the exact
mass observed. Isomers of a given molecular formula may
require further analytical separation and identification using
gas chromatography(GC)–MS or liquid chromatography–
MS/MS. This technique is also highly precise. Carbonyl
compounds were detected over a wide range of concentra-
tions by FT-ICR-MS, from 8 nmol/L for 2-butanone to
7 3 105 nmol/L for 4-hydroxyhexenal.27 Furthermore,
the carbonyl mass spectra provide a library of hard data
that can be retrieved and reanalyzed as new markers are
postulated.
Recent publications referencing a gold, nanoparticle-
based, gas sensor nanoarray detection device are enticing.
In a smaller sample set than in the current study, Peled
et al.10 were able to distinguish benign from malignant
disease and early from advanced disease, however a specific
comparison of early lung cancer with benign disease was
not given. A similar gas sensor nanoarray study in conjunc-
tion with GC-MS followed patients postoperatively and
demonstrated that the levels of specific volatile compounds
were increased when cancer was present and returned to
normal levels postoperatively.30gery c September 2014
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cancer before diagnostic breath analysis would be incisive
in determining the added benefit of our breath analysis
method. PET scans in patients with bulky disease frequently
result in false-positives for truly benign conditions as
demonstrated by the low specificity of PET scans. This
breath analysis method provides the potential for a cheaper
and more reliable diagnostic option for patients found to
have bulky disease on CT scans. If negative by breath anal-
ysis, the patient may be followed clinically without tissue
diagnosis. If positive by breath analysis, then the patient
may proceed to definitive biopsy, thus expediting the treat-
ment of lung cancer.
Our study has several limitations. Control subjects were
younger and healthy with no known active pulmonary dis-
ease, which may represent a bias. The proportion of patients
with benign disease is low and further studies that specif-
ically compare a larger number of patients with solitary pul-
monary nodules and lung cancer is warranted. A search for
disease processes that may produce the same carbonyl can-
cer markers is ongoing. Preliminary data among patients
with cystic fibrosis and pulmonary fibrosis has not indicated
any interference of carbonyl markers. Environmental and
genetic factors can be addressed by studying relatives of pa-
tients with cancer. Age-matched controls and specific
studies on patients with chronic obstructive pulmonary dis-
ease are warranted.
The significance of our data is reinforced by the normal-
ization of 3 of the 4 cancer markers within 1 month of can-
cer resection. Postoperative studies need to be extended to
all patients after resection with serial follow-up to deter-
mine if breath analysis can serve as a marker for tumor
recurrence. This study also needs to be extended to cancers
of different origin to determine applicability beyond lung
cancer. The finding that metastatic disease to the lung pro-
duced increased levels of carbonyl markers is enticing, and
promotes the concept that these markers may be found in
other primary tumors. A larger data set is needed to further
refine our results and compare its diagnostic usefulness with
screening CT scans. By resetting the cancer marker concen-
tration parameters to ensure maximum sensitivity, a pro-
spective study comparing screening CT scans and breath
analysis could be performed.
CONCLUSIONS
The increased concentrations of 2-butanone, 3-hydroxy-
2-butanone, 2-hydroxyacetaldehyde, and 4-hydroxyhexe-
nal in exhaled breath can be used for the diagnosis of
lung cancer. The sensitivity and specificity of breath anal-
ysis are related to the number of the ECMs. Breath analysis
has similar sensitivity to PET for the diagnosis of lung can-
cer, but has much higher specificity than PET in distinguish-
ing benign disease. Patients with lung metastases also
demonstrated ECMs. After resection of lung cancer, 3 ofThe Journal of Thoracic and Car4 cancer markers decreased to healthy control range. The
judicious use of these findings may expedite the care and in-
fluence decision-making in patients with potential lung
cancer.
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Dr Chukwumere Nwogu (Buffalo, NY). Dr Bousamra, I
congratulate you and your colleagues for this really intriguing
study and your excellent presentation.
With the anticipated marked increase in the number of small
lung nodules that we will probably need to evaluate as CT scan
screening for lung cancer gets really deployed in the community,
I think it is beneficial to have cost-effective tools to refine our man-
agement algorithms and to potentially avoid unnecessary or even
harmful procedures. I think this is very timely. I know it is early
in its development, but I find it very attractive. I also thank you
for providing the manuscript ahead of time.
I have 3 questions for you. In your estimation, what do you think
the estimated cost of this breath analysis would be for an individual
patient and how reproducible is it in various laboratories?
Dr Bousamra. The cost of doing the test right now is about $45.
There is the mass spectrometry charge, fee. The silicone wafers
cost a couple of dollars apiece. The chemical coating is very inex-
pensive. Then you would have to hire somebody to do the mass
spectrometry analysis if this was going to be a system-wide test.
I would estimate that the cost to an insurer would probably be
$200. We have not yet demonstrated reproducibility at other
institutions.
The next thing we want to do is enroll 2 or 3 times as many pa-
tients in the next year to confirm the results that we have already
have or to modify them. Quite frankly, when you begin something,
you are not quite as standardized as you should be because you are
figuring out how to do it. I think we could bemore quantitative than
we were to begin with about collecting breath. Why did we miss
some of those patients? I did not have time to say it, but of the
12 misses in early-stage disease, 10 of themwere adenocarcinoma.
So it may be that we are missing indolent tumors. They were small
adenocarcinomas, well differentiated for the most part. But it
may also be that the patients just did not give us a single
exhaled breath. It may be that they cheated and breathed a couple
of times, so that most of the breath in the bag was dead-space
ventilation.
Dr Nwogu. You suggested using this to assess a patient with
bulky disease and maybe decide not to perform a biopsy on such
a patient. In my mind, it is more attractive to evaluate small le-
sions, especially screen-detected lesions. You looked at 37 patients
who had stage 0 or stage I tumors that were less than 3 cm. You
quoted some values for the sensitivity of your breath analysis1080 The Journal of Thoracic and Cardiovascular Surversus PET scan, but in that particular subset of patients, what
was the specificity of the analysis?
Dr Bousamra. Well, the specificity is the same. It is still
dependent on the number of carbonyls that you choose to be pos-
itive. If we define 2 or more carbonyl compounds as being pos-
itive, for those small lesions we have a sensitivity of 73% and a
specificity of about 80%. In my thinking on helping to avoid
intervention in benign diseases, I agree with you, it is not the pri-
mary problem. The big factor is that we have got to study or see
how we do with 1-cm, 1.5-cm, 0.7-cm lesions that are detected
on a screening CT scan. That is the elephant in the room. But,
oh, by the way, the test never misses bigger tumors, at least in
our experience. If the tumor was bigger than 3 cm, breath anal-
ysis was never wrong. Say a patient has a 3-cm hilar lesion and
you think it is histoplasmosis, but it is active on PET and every-
body is worried to death about it, but if the patient blows a stone-
cold negative breath analysis, it really probably is negative, and
that can be reassuring. You are not going to perform a biopsy on
it 3 or 4 times. I am not saying that I am going to do that
tomorrow, but maybe if the data are confirmed in a larger study,
it could be helpful and reassuring to the patient and to the
clinician.
Dr Nwogu. Have you considered combining the findings from
the PETand your breath analysis? For instance, if you combine the
2 studies, the 2 tests, on a single patient, would you be able to in-
crease the sensitivity and specificity even further?
Dr Bousamra.No. We looked at that, and it did not really work
out that way. I threw out a slide that looked at the benign patients
and where they were false-negative and false-positive. They
migrate together to a fair extent. I do not have enough benign pa-
tients to really answer that confidently, but so far they have not
been helpful in combination.
Dr Akif Turna (Istanbul, Turkey). Did you look at the diabetes
status of the patients and the consumption of alcohol in these 2
groups, especially 3 to 5 hours before the test, and the glucose level
of the patients? That may affect the ketone bodies and the alde-
hydes in the blood.
Dr Bousamra. We did record what their diet was. Most of the
tests were taken early in the morning, so I hope they were not
drinking too much in the few hours before. We did not specifically
record alcohol intake. The point about these compounds is that
they are very specific to cancer. We do not find alcohol-related
compounds in increased concentrations. The glucose in the dia-
betics, they had higher levels of acetate, but not the carbonyls
we were interested in.
Dr Daniel Miller (Marietta, Ga). Excellent presentation.
I have 2 questions. Was there a difference with regard to histol-
ogy -adenocarcinoma versus squamous? The second question, for
your healthy baseline individuals, did you study any patients with
head and neck cancer? I think this would be important because of
the relationship between aerodigestive cancers and smoking; your
test could be positive for a head and neck cancer that was unde-
tected instead of a lung cancer.
Dr Bousamra. To answer the second question, yes, we have a
few head and neck cancers that I did not present and they were pos-
itive. We also have a variety of other cancers that are metastatic to
the lung that were positive on exhaled breath.
What was the first question?gery c September 2014
Bousamra et al Evolving Technology/Basic ScienceDrMiller.Was there a difference between adenocarcinoma and
squamous?
Dr Bousamra. There is a cancer marker profile that is specific
for small cell lung cancer. Pentanone and n-pentanal are more
diagnostic of small cell tumors. But I do not know whether that
is a tumor volume relationship. Also, 2-butanone is higher for
stages beyond stage I, as we noticed a difference between those
2. We did not find any strong correlation differentiating between
adenocarcinoma and squamous cell carcinoma.The Journal of Thoracic and CarDr Miller. Can you do this test with urine?
Dr Bousamra. Well, Linus Pauling did.
DrMiller. Smell it, sniff it? Bring a dog in here and wewill let it
smell your urine. (Laughter.)
Dr Bousamra. It is a good question.
DrMiller. But you cannot fake a urine test. Well, some athletes
can, but most of the time a patient will not fake a urine test.
Dr Bousamra. It is a good question and we should look at
whether a combined analysis would be beneficial.diovascular Surgery c Volume 148, Number 3 1081
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